secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001193125-22-069441
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics finalizes employment agreements for CEO ($425k) and CSO (£260k)
--------------------------------------------------------------------------------

- CEO Dr. Buell: $425,000 base salary, 50% bonus target, compensation retroactive to Jan 1, 2022.
- CSO Dr. van Dijk: £260,000 base salary, £18,000 housing/travel budget, 35% bonus target.
- Without cause termination: Buell receives 12 months salary, bonus, COBRA, and $15k outplacement.
- Change-in-control: Buell gets 18 months salary plus 150% bonus, full vesting acceleration of equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312522069441/0001193125-22-069441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312522069441/d69538d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-069441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer